February 10, 2026

TempraMed Technologies Ltd.
TempraMed Partners with Super-Pharm, Israel’s Leading Pharmacy Chain to Commence a National Product Roll Out Strategy

TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board

TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients

TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg

TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
